Navigation Links
CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Lazard Capital Markets 7th Annual Healthcare Conference at The St. Regis Hotel in New York City.

Steven G. Anderson, president and CEO of CryoLife, Inc., will present a corporate overview on Tuesday, November 16, 2010 at 4:10 p.m., Eastern Time.

CryoLife's live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page.  An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLifeFounded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  The Company's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  The Company's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  The Company's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife currently distributes HemoStase®, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in many international markets for cardiac, vascular, and general surgery, subject to certain exclusions, although CryoLife has received notice from Medafor, Inc. that it has terminated its HemoStase distribution agreement with CryoLife.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.Media Contact:D. Ashley LeeExecutive Vice President, Chief Financial Officer andChief Operating OfficerPhone: 770-419-3355
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
2. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
3. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
4. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
5. CryoLife Provides Initial 2010 Financial Guidance
6. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
7. CryoLife to Present at Upcoming Investor Conferences in New York
8. CryoLife Reports Record Quarterly Revenues of $28.2 Million
9. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
10. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
11. Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Based on ... safety and efficacy of HBOT in treating and helping to heal addictions and ... research showing the similarities of the wounds to the brain from traumatic brain ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... healthcare industry, made the 2017 Inc. 5000 with a three-year sales growth ... nation’s fastest-growing private companies and comprises the most comprehensive look at America’s independent ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... the American Academy of Orthopaedic Surgeons , points out that therapeutic modalities ... from pain or injury. According to the report, a wider scope of physical ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
Breaking Medicine News(10 mins):